Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AWHNASDAQ:BIORNASDAQ:REVBNASDAQ:TNFA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAWHAspira Women's Health$0.08-12.5%$0.09$0.08▼$2.53$2.44M2.011.39 million shs4.31 million shsBIORBiora Therapeutics$0.14-3.6%$0.14$0.15▼$7.90$995K1.1271,706 shs4,271 shsREVBRevelation Biosciences$0.90+9.4%$2.77$0.77▼$60.80$868K0.19333,549 shs46.73 million shsTNFATNF Pharmaceuticals$0.17-1.9%$0.23$0.15▼$2.16$2.38M2.13825,012 shs1.73 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAWHAspira Women's Health0.00%0.00%0.00%-46.23%-96.68%BIORBiora Therapeutics0.00%+3.70%+1.38%0.00%-97.81%REVBRevelation Biosciences-3.51%-66.13%-71.22%-76.14%-97.33%TNFATNF Pharmaceuticals+3.26%-1.95%-15.01%-55.35%+17,099,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAWHAspira Women's Health1.1038 of 5 stars3.50.00.00.01.10.00.0BIORBiora Therapeutics1.7552 of 5 stars3.50.00.00.00.02.50.6REVBRevelation Biosciences1.6049 of 5 stars0.05.00.00.03.10.01.3TNFATNF PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAWHAspira Women's Health 3.00Buy$5.506,607.32% UpsideBIORBiora Therapeutics 3.00Buy$23.0016,937.04% UpsideREVBRevelation Biosciences 0.00N/AN/AN/ATNFATNF Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAWHAspira Women's Health$9.18M0.27N/AN/A($0.23) per share-0.36BIORBiora Therapeutics$892K0.68N/AN/A($36.43) per share0.00REVBRevelation BiosciencesN/AN/AN/AN/A$402.10 per shareN/ATNFATNF PharmaceuticalsN/AN/AN/AN/A$7.21 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAWHAspira Women's Health-$16.69M-$0.98N/A∞N/A-165.07%N/A-267.23%8/11/2025 (Estimated)BIORBiora Therapeutics-$124.11M-$13.04N/AN/AN/AN/AN/A-332.47%6/5/2025 (Estimated)REVBRevelation Biosciences-$120K-$102.61N/AN/AN/AN/A-193.51%-84.00%8/8/2025 (Estimated)TNFATNF Pharmaceuticals-$4M-$6.67N/A∞N/AN/A-180.71%-84.27%8/18/2025 (Estimated)Latest BIOR, AWH, TNFA, and REVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025TNFATNF PharmaceuticalsN/A-$0.36N/A-$0.36N/AN/A5/8/2025Q1 2025REVBRevelation Biosciences-$6.88-$2.11+$4.77-$2.11N/AN/A4/11/2025Q4 2024TNFATNF PharmaceuticalsN/A-$0.66N/A-$0.66N/AN/A3/27/2025Q4 2024AWHAspira Women's Health-$0.21-$0.08+$0.13-$0.08$3.00 million$2.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAWHAspira Women's Health$1.041,268.29%N/AN/A N/ABIORBiora TherapeuticsN/AN/AN/AN/AN/AREVBRevelation BiosciencesN/AN/AN/AN/AN/ATNFATNF PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAWHAspira Women's HealthN/A0.750.70BIORBiora TherapeuticsN/A0.050.05REVBRevelation BiosciencesN/A1.641.64TNFATNF PharmaceuticalsN/A1.721.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAWHAspira Women's Health12.19%BIORBiora Therapeutics43.74%REVBRevelation Biosciences12.80%TNFATNF Pharmaceuticals9.64%Insider OwnershipCompanyInsider OwnershipAWHAspira Women's Health4.30%BIORBiora Therapeutics51.08%REVBRevelation Biosciences0.06%TNFATNF Pharmaceuticals1.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAWHAspira Women's Health11029.76 million16.92 millionNo DataBIORBiora Therapeutics1204.52 million2.21 millionOptionableREVBRevelation Biosciences10964,000268,000Not OptionableTNFATNF Pharmaceuticals614.18 million2.72 millionN/ABIOR, AWH, TNFA, and REVB HeadlinesRecent News About These CompaniesHead-To-Head Comparison: Aspira Women's Health (NASDAQ:AWH) vs. TNF Pharmaceuticals (NASDAQ:TNFA)June 2 at 1:11 AM | americanbankingnews.comTNF Pharmaceuticals Amends Bylaws to Alter Voting RulesMay 9, 2025 | tipranks.comTNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 AgonistsMay 8, 2025 | businesswire.comTNF Pharmaceuticals uses AI to refine patient selection for trialsApril 24, 2025 | uk.investing.comTNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug DevelopmentApril 22, 2025 | finance.yahoo.comTNF Pharmaceuticals To Use AI To Recruit Patients For Drug Development: Retail Stays BearishApril 22, 2025 | msn.comTNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025April 17, 2025 | finance.yahoo.comTNF Pharmaceuticals, Inc. Common Stock (TNFA) Short InterestApril 3, 2025 | nasdaq.comTNF Pharmaceuticals faces Nasdaq delisting over priceMarch 23, 2025 | investing.comTNF Pharmaceuticals, Inc. Common StockMarch 20, 2025 | fxempire.comTNF Pharmaceuticals shares R&D progress on IsomyosamineMarch 12, 2025 | uk.investing.comTNF Pharmaceuticals initiates isomyosamine trialFebruary 25, 2025 | markets.businessinsider.comTNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha InhibitorFebruary 25, 2025 | businesswire.comTNFA stock touches 52-week low at $0.48 amid market challengesFebruary 14, 2025 | msn.comTNFA stock touches 52-week low at $1.02 amid market challengesJanuary 30, 2025 | msn.comHow Does TNF Pharmaceuticals Inc (TNFA) Stack Up Against Its Industry Peers?January 30, 2025 | bovnews.comTNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss TreatmentJanuary 29, 2025 | tmcnet.comTNF Pharmaceuticals to study TNF-alpha in patients taking GLP-1sJanuary 29, 2025 | markets.businessinsider.comTNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial ExpansionJanuary 15, 2025 | finance.yahoo.comTNF Pharmaceuticals, Inc. (TNFA)December 10, 2024 | au.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBIOR, AWH, TNFA, and REVB Company DescriptionsAspira Women's Health NASDAQ:AWH$0.08 -0.01 (-12.49%) As of 04/16/2025Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.Biora Therapeutics NASDAQ:BIOR$0.14 -0.01 (-3.57%) As of 06/2/2025Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.Revelation Biosciences NASDAQ:REVB$0.90 +0.08 (+9.44%) Closing price 04:00 PM EasternExtended Trading$0.88 -0.02 (-1.85%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.TNF Pharmaceuticals NASDAQ:TNFA$0.17 0.00 (-1.87%) Closing price 04:00 PM EasternExtended Trading$0.17 +0.00 (+0.12%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Broadcom Earnings Preview: AVGO Stock Near Record Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
